Skip to main content

Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc.VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. (“NIC”) (the “Transaction”) previously announced on May 13, 2025. The Transaction moves Algernon into the Alzheimer’s Disease (“AD”) diagnostic and treatment market,...

Continue reading

IMG Academy Announces Acquisition of College Recruiting Service SportsRecruits

SportsRecruits Joins NCSA College Recruiting as IMG Academy Services Aimed at Helping Student-Athletes and Coaches Navigate the Evolving College Sports Recruiting Landscape BRADENTON, Fla., May 22, 2025 (GLOBE NEWSWIRE) — IMG Academy, the world’s leading sports education brand, today announced the acquisition of SportsRecruits, a college sports recruiting service with specialized products for families, club and high school teams, college coaches and event operators. The acquisition brings SportsRecruits alongside IMG Academy’s NCSA College Recruiting to create an even more robust college sports recruiting network to help student-athletes and their families navigate the ever-evolving college sports landscape. The terms of the deal were not disclosed. The acquisition marks a significant milestone for IMG Academy as it continues to...

Continue reading

UPDATE – Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) — Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following the public disclosure of the agreement in a Form 8-K filed by POAI on January 6, 2025, POAI’s stock price rose by more than 50%. Renovaro alleges...

Continue reading

Upon the recommendation of the ad hoc Committee, the Supervisory Board of Tarkett reiterates a favourable reasoned opinion on the fairness of the public buy-out Offer followed by a squeeze-out

Upon the recommendation of the ad hoc Committee, the Supervisory Board of Tarkett reiterates a favourable reasoned opinion on the fairness of the public buy-out Offer followed by a squeeze-out. This favourable reasoned opinion follows the submission by Finexsi of an addendum to its fairness opinion confirming the fairness of the Offer. PARIS, FRANCE, 22 MAY 2025 – Following observations by certain minority shareholders of Tarkett concerning the public buy-out offer followed by a squeeze-out (OPR-RO) on Tarkett shares initiated by Tarkett Participation at a price of €17 per share1 (the “Offer”) and the submission by Finexsi, acting as independent expert2, of an addendum to its fairness opinion confirming the fairness of the Offer, the Supervisory Board of Tarkett, based on the recommendation of the ad hoc Committee, reiterated its...

Continue reading

Urbana Corporation Congratulates the Canadian Securities Exchange on its Acquisition of the National Stock Exchange of Australia

/NOT FOR DISTRIBUTION TO U.S. WIRE SERVICESOR FOR DISSEMINATION IN THE U.S./ TORONTO, May 22, 2025 (GLOBE NEWSWIRE) — Urbana Corporation (“Urbana” or the “Corporation”) (TSX and CSE: URB, URB.A) congratulates CSNX Markets Inc. (“CSE”) on its entering into an agreement with the NSX Limited (“NSX”) to acquire the NSX, owner of the National Stock Exchange of Australia (“NSXA”) in an all-cash transaction (the “Transaction”). This acquisition will enable the CSE to expand its geographic footprint by partnering with an exchange that has a similar focus and culture. Like the CSE, the NSXA is primarily focused on early stage, entrepreneurial companies, with particular strength in the resource sector. The NSXA is positioned to disrupt a market currently dominated by an incumbent, legacy exchange, as the CSE was over 20 years...

Continue reading

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) — Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock. Following the public disclosure of the agreement in a Form 8-K filed by POAI on January 6, 2025, POAI’s stock price rose by more than 50%. Renovaro alleges...

Continue reading

Matachewan Announces Purchase and Sale Agreement to Mineral Royalties

TORONTO, May 22, 2025 (GLOBE NEWSWIRE) — Matachewan Consolidated Mines, Limited (“Matachewan” or the “Company”) (TSX-V:MCM.A-X) is pleased to announce that the Company has entered into a definitive purchase and sale agreement (the “Agreement”) with respect to the sale of certain of its mineral royalties on the Young-Davidson Mine, located in the Matachewan, Ontario area, to Alamos Gold Inc. (“Alamos”) (the “Purchaser”) owner and operator of the Young-Davidson Mine. The transaction closed on the 21st day of May 2025. Prior to closing of the transaction, the Company was the legal and beneficial owner of certain royalty rights on 24 mining claims in Powell and Cairo Townships, Matachewan, Ontario which forms part of the Young-Davidson Mine owned and operated by Alamos. Pursuant to the Agreement, the Company sold all of its rights...

Continue reading

Form 8.3 – [CRANEWARE PLC – 21 05 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree CRANEWARE PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

– Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 – – Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer’s disease – – Companies expect transaction to close in third quarter of 2025 – WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases and Sanofi (NASDAQ: SNY), today announced that it has entered into a definitive...

Continue reading

Highrock Resources Options Ontario Gold Property

TORONTO, May 21, 2025 (GLOBE NEWSWIRE) — Highrock Resources Ltd. (“Highrock” or “the Company”) (CSE: HRK) is pleased to announce that it has entered into an option agreement (the “Option Agreement“) with an arm’s length optionor (the “Optionor“) dated May 12, 2025 (the “Effective Date“), pursuant to which the Company was granted an option (the “Option“) to acquire seven (7) mining claims (116 units) (the “Property“). in the Minnitaki Lake area located between the towns of Dryden and Sioux Lookout in Northwest Ontario. Several historical gold showings are located in the sequence of Archean mafic metavolcanics, metasediments and iron formation which trend ENE through the general area of the property, The area has recently been the focus of gold...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.